Dr Reddy's Laboratories today said it has successfully completed the USD 350 million (around Rs 2,300 crore) acquisition of eight abbreviated new drug applications (ANDAs) in the US from Teva Pharmaceutical Industries and an affiliate of Allergan plc.
The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
The portfolio being acquired is a mix of filed ANDAs pending approval and an approved ANDA and comprises complex generic products across diverse dosage forms, Dr Reddy's Laboratories said in a statement.
The combined sales of the branded versions of the products in the US are around USD 3.5 billion, it added.
